Find clinical trials for Chronic Lymphocytic Leukemia in Barcelona, CT
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Chronic Lymphocytic Leukemia trials near Barcelona, CT, ESP:
100 mg twice daily (bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be e...
Phase 3
Barcelona, Spain and 108 other locations
A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic ...
Phase 3
Barcelona, Spain and 40 other locations
together in participants with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (Part A - Dose Esca...
Phase 1
Barcelona, Spain and 27 other locations
The purpose of the First-In-Human study is to assess safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of JBH492 a...
Phase 1
Barcelona, Catalunya, Spain and 7 other locations
monotherapy in participants with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). This study will also all...
Phase 1
Barcelona, Spain and 17 other locations
objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic...
Phase 3
Hospitalet de LLobregat, Spain and 175 other locations
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing o...
Phase 2
Barcelona, Spain and 59 other locations
The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL wh...
Phase 3
Barcelona, Spain and 107 other locations
This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic...
Phase 3
Barcelona, Spain and 130 other locations
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic...
Phase 3
Barcelona, Spain and 120 other locations
Clinical trials
Research sites
Resources
Legal